STOCK TITAN

Health Catalyst (HCAT) SEC Filings

HCAT NASDAQ

Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.

The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.

Rhea-AI Summary

Health Catalyst, Inc. (HCAT) General Counsel Benjamin Landry reported direct sales of 70,000 common shares on November 11, 2026, at $1.4289 per share and 29,478 shares on November 12, 2026, at $1.3892 per share. Across both transactions, the reported sales totaled 99,478 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. officer Benjamin Landry reported a proposed sale of 29,478 common shares, with an aggregate market value of $42,153.54 and an approximate sale date of November 12, 2026. The shares were acquired upon vesting of restricted stock units between February 25 and September 1, 2026. The notice gives August 12, 2026 as the Rule 10b5-1 plan adoption or instruction date. Benjamin Landry's reported 10b5-1 sales also include 70,000 shares for gross proceeds of $100,023.00 on November 11, 2026, and 13,167 shares for $22,431.30 on September 1, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
other
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) officer Benjamin Landry reported 99,478 common shares to be sold, with an aggregate market value of $143,248.32 and an approximate sale date of November 11, 2026. The remarks state that sales executed on November 11 are being reported in the notice.

The shares were acquired through restricted stock unit vesting from February 25 through September 1, 2026. The notice lists August 12, 2026 as the date of plan adoption or giving of instruction under Rule 10b5-1. It also lists Landry's sale of 13,167 common shares on September 1, 2026, for gross proceeds of $22,431.30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.90%
Tags
other
Rhea-AI Summary

Health Catalyst, Inc. reported third-quarter revenue of $56.283 million, compared with $76.323 million a year earlier. Net income attributable to common stockholders was $40.496 million, versus a $22.229 million loss, and included a $65.9 million gain on the sale of the Vitalware business. For the first nine months, revenue was $197.526 million versus $236.457 million, while net loss was $111.067 million versus $86.949 million; results included $122.548 million of goodwill impairment.

Health Catalyst completed the sale of the Vitalware business to Med-Metrix on July 31, 2026. Closing consideration was $146.3 million, net of transaction expenses and estimated net working capital adjustments, including net initial cash proceeds of $144.5 million; approximately $1.8 million of additional consideration, including escrow receivables, is expected within the next year. The company used the initial proceeds and cash on hand to repay all credit-agreement obligations, with no amounts outstanding as of September 30, 2026. Repayment generated a $9.5 million loss on extinguishment of debt. Net cash provided by operating activities was $16.911 million for the first nine months, compared with $9.181 million used in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
quarterly report
-
Rhea-AI Summary

Health Catalyst, Inc. reported third-quarter 2026 revenue of $56.283 million, down 26% year over year, and Adjusted EBITDA of $779,000, down 94%. Management said revenue and Adjusted EBITDA were above the high end of quarterly guidance. Gross profit was $17.345 million, down 42%, while GAAP net income was $40.496 million compared with a $22.229 million loss a year earlier; the company said net income was largely driven by a $65.889 million gain on the Vitalware sale. Health Catalyst attributed year-over-year declines in revenue, gross profit and Adjusted EBITDA primarily to the July 31, 2026 divestiture and headwinds from the DOS-to-Ignite migration, partly offset by cost reduction initiatives.

The company reaffirmed full-year 2026 guidance of $246 million to $249 million in revenue and $18 million to $18.5 million in Adjusted EBITDA. The Vitalware transaction closed July 31, 2026, with $146.3 million total consideration received; Health Catalyst used net cash proceeds and cash on hand to repay all outstanding Credit Agreement obligations and terminate the agreement. For the nine months ended September 30, 2026, net cash provided by operating activities was $16.911 million, compared with $9.181 million used in the prior-year period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
current report
-
Rhea-AI Summary

Health Catalyst, Inc. director Tami Reller acquired an award of 128,851 restricted stock units on October 1, 2026. Each RSU represents a contingent right to receive one common share. The transaction table reports a direct post-transaction position of 128,851 shares; the footnote identifies the award as RSUs. Under the 2019 Plan and the Non-Employee Director Compensation Policy, 33.33% vest on October 1, 2027, and the remaining 66.67% vest in two equal annual installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
insider
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) identifies Tami Reller as a director in an initial beneficial-ownership report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) reported that Chief Executive Officer and director Simeon Kohl received a grant of 2,747,385 restricted stock units (RSUs) on September 14, 2026 under the company’s 2026 Employment Inducement Incentive Plan. 915,975 RSUs vest on September 4, 2027, with the remaining RSUs vesting in eight approximately equal quarterly installments thereafter, subject to plan terms. On the same date, he also purchased 59,000 shares of common stock at $1.7871 per share in a direct transaction. No Rule 10b5-1 trading plan is indicated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
insider
-
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) disclosed that Simeon Kohl, its Chief Executive Officer and a director, beneficially owns 25,000 shares of common stock. According to the accompanying footnote, Kohl acquired an aggregate of 25,000 shares on September 11, 2026 through an open market purchase at a weighted average price of $1.76427 per share, and these shares are now held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
insider
Rhea-AI Summary

Health Catalyst, Inc. (HCAT) reported that on September 11, 2026, it appointed Tami Reller to its board of directors as a Class III director, with her service effective October 1, 2026, expanding the board from six to seven members. She will serve as chair of the Audit Committee, replacing Justin Spencer in that role while he remains on the committee, and will join the Compensation Committee, replacing Jill Hoggard Green there. The company highlights Reller’s extensive executive experience at Duly Health and Care, subsidiaries of UnitedHealth Group, and Microsoft, as well as her public-company board service. A contemporaneous press release describes Health Catalyst as an AI-forward healthcare intelligence company built on 18 years of results and $2.8 billion in validated outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
current report

FAQ

How many Health Catalyst (HCAT) SEC filings are available on StockTitan?

StockTitan tracks 127 SEC filings for Health Catalyst (HCAT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Health Catalyst (HCAT)?

The most recent SEC filing for Health Catalyst (HCAT) was filed on November 13, 2026.